Positron Emission Tomography (PET) of 18 kDa translocator protein (TSPO) has been investigated as putative marker of neuroinflammation but faces substantial methodological challenges. These include issues with arterial blood sampling for kinetic modeling, the absence of suitable reference regions, genetic polymorphisms affecting tracer affinity, altered blood-to-brain tracer delivery in inflammatory conditions, and high signal variability. This study presents a novel blood-free reference-free method for TSPO PET quantification, leveraging a logistic regression model to estimate the probability of TSPO overexpression across brain regions. Validation was performed on 323 human brain scans from five datasets and three radiotracers. The quantified TSPO topology in healthy controls showed strong concordance with constitutive TSPO gene expression for all tracers. When using [11C]PBR28 PET data, the method replicated previous findings in schizophrenia, Alzheimer’s disease, chronic pain, and XBD173 blocking. However, model extension to [18F]DPA-714 and [11C]-(R)-PK11195 revealed small effect sizes and high variability, suggesting the need for tracer-specific model optimization. Finally, validation in a rat model of lipopolysaccharide-induced neuroinflammation confirmed previous evidence of increased brain TSPO uptake after systemic challenge. This novel non-invasive method provides individualized TSPO PET quantification, demonstrating broad applicability across TSPO PET tracers and imaging sites, assuming sufficient training data for model development.
DupontA-CLargeauBSantiago RibeiroM, et al.
Translocator protein-18 kDa (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases. IJMS2017;
18: 785.
2.
JainPChaneyAMCarlsonML, et al.
Neuroinflammation PET imaging: current opinion and future directions. J Nucl Med2020;
61: 1107–1112.
3.
Cosenza-NashatMZhaoM-LSuhH-S, et al.
Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol2009;
35: 306–328.
4.
LavisseSGuillermierMHérardA-S, et al.
Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci2012;
32: 10809–10818.
5.
Vicente-RodríguezMSinghNTurkheimerF, et al.
Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation. Brain Behav Immun2021;
96: 154–167.
6.
Vicente-RodríguezMMancusoRPeris-YagueA, et al.
Pharmacological modulation of TSPO in microglia/macrophages and neurons in a chronic neurodegenerative model of prion disease. J Neuroinflamm2023;
20: 92.
7.
NutmaEFancyNWeinertM, et al.
Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases. Nat Commun2023;
14: 5247.
8.
NutmaEStephensonJAGorterRP, et al.
A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis. Brain2019;
142: 3440–3455.
9.
WijesingheSSRoweJBMasonHD, et al.
Post-mortem validation of in vivo TSPO PET as a microglial biomarker. Brain2025;
148: 1904–1910.
10.
CummingPBurgherBPatkarO, et al.
Sifting through the surfeit of neuroinflammation tracers. J Cereb Blood Flow Metab2018;
38: 204–224.
11.
Dimitrova-ShumkovskaJKrstanoskiLVeenmanL.Diagnostic and therapeutic potential of TSPO studies regarding neurodegenerative diseases, psychiatric disorders, alcohol use disorders, traumatic brain injury, and stroke: an update. Cells2020;
9: 870.
12.
KreislWCLyooCHMcGwierM, et al.
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain2013;
136: 2228–2238.
13.
LoggiaMLChondeDBAkejuO, et al.
Evidence for brain glial activation in chronic pain patients. Brain2015;
138: 604–615.
14.
BodiniBToniettoMAirasL, et al.
Positron emission tomography in multiple sclerosis – straight to the target. Nat Rev Neurol2021;
17: 663–675.
15.
De PickerLJMorrensMBranchiI, et al.
TSPO PET brain inflammation imaging: a transdiagnostic systematic review and meta-analysis of 156 case-control studies. Brain Behav Immun2023;
113: 415–431.
16.
ToniettoMRizzoGVeroneseM, et al.
A unified framework for plasma data modeling in dynamic positron emission tomography studies. IEEE Trans Biomed Eng2019;
66: 1447–1455.
17.
ToniettoMRizzoGVeroneseM, et al.
Plasma radiometabolite correction in dynamic PET studies: insights on the available modeling approaches. J Cereb Blood Flow Metab2016;
36: 326–339.
18.
AlbrechtDSGranzieraCHookerJM, et al.
In vivo imaging of human neuroinflammation. ACS Chem Neurosci2016;
7: 470–483.
19.
TurkheimerFERizzoGBloomfieldPS, et al.
The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans2015;
43: 586–592.
20.
LockhartADavisBMatthewsJC, et al.
The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant alpha1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker. Nuclear Medicine and Biology
21.
NettisMAVeroneseMNikkheslatN, et al.
PET imaging shows no changes in TSPO brain density after IFN-α immune challenge in healthy human volunteers. Transl Psychiatry2020;
10: 89.
22.
TurkheimerFEAlthubaityNSchubertJ, et al.
Increased serum peripheral C-reactive protein is associated with reduced brain barriers permeability of TSPO radioligands in healthy volunteers and depressed patients: implications for inflammation and depression. Brain Behav Immun2021;
91: 487–497.
23.
LammertsmaAAHumeSP.Simplified reference tissue model for PET receptor studies. NeuroImage1996;
4: 153–158.
24.
SchubertJToniettoMTurkheimerF, et al.
Supervised clustering for TSPO PET imaging. Eur J Nucl Med Mol Imaging2021;
49: 257–268.
25.
TurkheimerFEEdisonPPaveseN, et al.
Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med2007;
48: 158–167.
26.
Plavén-SigrayPCervenkaS.Meta-analytic studies of the glial cell marker TSPO in psychosis – a question of apples and pears?: a commentary on ‘neuroinflammation in schizophrenia: metaanalysis of in-vivo microglial imaging’ by marques. Psychol Med2019;
49: 1624–1628.
27.
WerryELBrightFMPiguetO, et al.
Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders. Ijms2019;
20: 3161.
28.
EiffBBullmoreETClatworthyMR, et al. Extra-axial inflammatory signal and its relation to peripheral and Central immunity in depression. Brain2024;
148: 635–646.
29.
EricksonMADohiKBanksWA.Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier. Neuroimmunomodulation2012;
19: 121–130.
30.
TurkheimerFEVeroneseMMondelliV, et al.
Sickness behaviour and depression: an updated model of peripheral-central immunity interactions. Brain Behav Immun2023;
111: 202–210.
31.
OwenDRYeoAJGunnRN, et al.
An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab2012;
32: 1–5.
32.
LaaksonenSSarasteMNylundM, et al.
Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals. Front Neurol2024;
15: 1352116.
33.
PeyronneauMKuhnastBNguyenD-L, et al.
[18F]DPA-714: effect of co-medications, age, sex, BMI and TSPO polymorphism on the human plasma input function. Eur J Nucl Med Mol Imaging2023;
50: 3251–3264.
34.
TuiskuJPlavén-SigrayPGaiserEC, et al.
Effects of age, BMI and sex on the glial cell marker TSPO – a multicentre [11C]PBR28 HRRT PET study. Eur J Nucl Med Mol Imaging2019;
46: 2329–2338.
35.
BloomfieldPSSelvarajSVeroneseM, et al.
Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [11 C]PBR28 PET brain imaging study. Am J Psychiatry2016;
173: 44–52.
36.
NairAVeroneseMXuX, et al.
Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer’s disease. EJNMMI Res2016;
6: 72.
37.
AlbrechtDSForsbergASandströmA, et al.
Brain glial activation in fibromyalgia – a multi-site positron emission tomography investigation. Brain Behav Immun2019;
75: 72–83.
38.
VeroneseMReis MarquesTBloomfieldPS, et al.
Kinetic modelling of [11 C]PBR28 for 18 kDa translocator protein PET data: a validation study of vascular modelling in the brain using XBD173 and tissue analysis. J Cereb Blood Flow Metab2018;
38: 1227–1242.
39.
CousinsOSchubertJJChandraA, et al.
Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge. J Neuroinflammation2023;
20: 272.
40.
SchubertJVeroneseMFryerTD, et al.
A modest increase in 11C-PK11195-Positron emission tomography TSPO binding in depression is not associated with serum C-reactive protein or body mass index. Biol Psychiatry Cogn Neurosci Neuroimaging2021;
6: 716–724.
41.
HosmerDWLemeshowSSturdivantRX.Applied Logistic Regression.
New York:
John Wiley & Sons, 2013.
42.
MaccioniLMichelleCMBrusaferriL, et al.
A blood-free modeling approach for the quantification of the blood-to-brain tracer exchange in TSPO PET imaging. Front Neurosci2024;
18: 1395769.
43.
KreislWCJenkoKJHinesCS, et al.
A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab2013;
33: 53–58.
44.
TziortziACSearleGETzimopoulouS, et al.
Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. NeuroImage2011;
54: 264–277.
45.
BrykASRaudenbushSW.Hierarchical linear models: Applications and data analysis methods.
Thousand Oaks, CA:
Sage Publications, Inc, 1992.
46.
DegenholtzHBBhatnagarM.Introduction to hierarchical modeling. J Palliat Med2009;
12: 631–638.
47.
MarquesTRAshokAHPillingerT, et al.
Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. Psychol Med2019;
49: 2186–2196.
48.
ZhouRJiBKongY, et al.
PET imaging of neuroinflammation in Alzheimer’s disease. Front Immunol2021;
12: 739130.
49.
LinT-JLandryMP. Quantifying data distortion in bar graphs in biological research. bioRxiv 2024; 2024.09.20.609464.
50.
SridharanSLepelletierF-XTriggW, et al.
Comparative evaluation of three TSPO PET radiotracers in a LPS-induced model of mild neuroinflammation in rats. Mol Imaging Biol2017;
19: 77–89.
51.
MartinsDGiacomelAWilliamsSCR, et al.
Imaging transcriptomics: convergent cellular, transcriptomic, and molecular neuroimaging signatures in the healthy adult human brain. Cell Rep2021;
37: 110173.
52.
RizzoGVeroneseMToniettoM, et al.
Kinetic modeling without accounting for the vascular component impairs the quantification of [11 C]PBR28 brain PET data. J Cereb Blood Flow Metab2014;
34: 1060–1069.
53.
LyooCHIkawaMLiowJ-S, et al.
Cerebellum can serve As a Pseudo-Reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J Nucl Med2015;
56: 701–706.
54.
PolaIAshtonNJAntônio De BastianiM, et al.
Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer’s disease. Alzheimers Dement2025;
21: e70171.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
